NCT00947167 2017-03-03A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine TumorsStanford UniversityPhase 2 Terminated4 enrolled 5 charts
NCT00077454 2013-06-05Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsNational Cancer Institute (NCI)Phase 1 Completed95 enrolled